Grail, Inc. (GRAL)
NASDAQ (NGS) NASDAQ (NGS) Primary 
GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection October 20, 2025 8:00 AM EDT Company Participants Robert Ragusa - CEO & Director Joshua Ofman - President Harpal Kumar - President of International Business & BioPharma Aaron Freidin - Chief Financial Officer Conference Call Participants Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Yuko Oku - Morgan Stanley, Research Division Douglas Schenkel - Wolfe Research, LLC Presentation Operator Good day, ladies and gentlemen, and welcome to today's GRAIL analyst call. [Operator Instructions] Please be advised that this conference call is being recorded.
Grail: A Speculative Buy
Grail, Inc. represents a speculative long-term investment opportunity, conditional on the FDA's approval of its Galleri multi-cancer early detection blood test and its widespread adoption among the general population. Assuming FDA approval, GRAL could reach $100–$250 per share, based on reasonable assumptions regarding its total addressable market and the prevailing competitive landscape. Galleri's robust revenue growth as a predominantly self-paid test over the past three years provides a reasonable margin of safety against the risk of FDA non-approval.
GRAIL, Inc. (GRAL) Q2 2025 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Aaron Freidin - Chief Financial Officer Andrew John Partridge - Chief Commercial Officer Harpal S. Kumar - President of International Business & BioPharma Joshua J.
The Holy Grail of Automation: Now a Robot Can Unload a Truck
Technology breakthroughs are allowing DHL and other companies to automate the laborious, injury-prone work of loading and unloading.
3 Medical Technology Stocks Outperforming in 2025
As the broader market stages a sharp rebound from its April lows, several sectors, industries, and stocks have quietly emerged as leaders. Among them, the medical technology industry, known for its innovation and growth potential, has stood out.
GRAIL, Inc. (GRAL) Q1 2025 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Bob Ragusa - CEO Aaron Freidin - CFO Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Andy Partridge - Chief Commercial Officer Conference Call Participants Subbu Nabi - Guggenheim Partners Tejas Savant - Morgan Stanley Doug Schenkel - Wolfe Research Kyle Mikson - Canaccord Operator Good day, ladies and gentlemen. And welcome to the GRAIL First Quarter 2025 Earnings Call.
GRAIL's Galleri Progresses While Back In Accumulation Levels
GRAL's Galleri test is easily its main value driver at this point. This test can screen over 50 cancers with high sensitivity and accuracy. Post-spin-off from Illumina, GRAL has continued growing its revenues while also securing partnerships like Quest Diagnostics and TRICARE. GRAL's Galleri also secured the FDA's Breakthrough Device status, and its pivotal PMA submission should happen by 1H2026.
How Does GRAIL Benefit From The Proposed MCED Legislation?
GRAIL, Inc.'s Galleri test could see significant revenue growth if the bipartisan MCED bill passes, enabling Medicare reimbursement for FDA-approved multi-cancer early detection tests. Galleri's potential market includes 67 million Medicare beneficiaries, with a conservative estimate of $2.4 billion in revenue by the fifth year post-legislation. Despite promising financials and market leadership, Galleri's FDA approval is pending, and Medicare reimbursement may not start until 2028, posing short-term risks.
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Officer Joshua Ofman - President Sir Harpal Kumar - President of International Business and BioPharma Conference Call Participants Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the GRAIL Fourth Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer screening blood tests.
GRAIL: Biotech Stock Targeting $100B Cancer Market
GRAIL NASDAQ: GRAL is a small-cap biotechnology company that has gone on a very strong run over the last month and a half. Shares of the healthcare stock are up 58% since Oct. 24, as of the Dec. 11 close.
World's biggest hedge fund flags the ‘holy grail' that may shield investors if U.S. stock rally crumbles
Karen Karniol-Tambour, co-chief investment officer at Bridgewater Associates, says valuations are much higher for U.S. stocks than they were when the bull run began.
